Other Species / Isoforms
  caveolin-2 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
K7-ub
_MGLETEkADVQLFM
0 1
caveolin-2 (human) _MGLETEkADVQLFM K7-ub
caveolin-2 iso2 (human) under review -
caveolin-2 iso3 (human) _MGLETEKADVQLFM K7
caveolin-2 (mouse) _MGLETEKADVQLFM K7
caveolin-2 (rat) _MGLETEKADVQLFM K7
S18-p
QLFMDDDsysHHsGL
0 47
caveolin-2 (human) QLFMDDDsysHHsGL S18-p
caveolin-2 iso2 (human) ___MDDDSYSHHSGL S5
caveolin-2 iso3 (human) QLFMDDDSYSHHSGL S18
caveolin-2 (mouse) QLFMADDAysHHsGV A18
caveolin-2 (rat) QLFMADDAysHHSVV A18
Y19-p
LFMDDDsysHHsGLE
Upstream
Downstream
10 37
Effects on Modified Protein
  • intracellular localization
  • molecular association, regulation
  • phosphorylation
Effects on Biological Processes:
  • cell adhesion, induced
  • cell growth, induced
  • signaling pathway regulation
  • transcription, inhibited
Putative in vivo kinases:
  • Src (human)
Regulatory protein:
  • PROX1 (human)
Treatment
  • EGF
  • fibronectin
  • IGF-1
  • imatinib
  • insulin
  • nocodazole
  • PP2
  • TGF-beta
  • vanadate
caveolin-2 (human) LFMDDDsysHHsGLE Y19-p
caveolin-2 iso2 (human) __MDDDSYSHHSGLE Y6
caveolin-2 iso3 (human) LFMDDDSYSHHSGLE Y19
caveolin-2 (mouse) LFMADDAysHHsGVD Y19-p
caveolin-2 (rat) LFMADDAysHHSVVD Y19-p
S20-p
FMDDDsysHHsGLEy
Upstream
1 51
Treatment
  • imatinib
caveolin-2 (human) FMDDDsysHHsGLEy S20-p
caveolin-2 iso2 (human) _MDDDSYSHHSGLEY S7
caveolin-2 iso3 (human) FMDDDSYSHHSGLEY S20
caveolin-2 (mouse) FMADDAysHHsGVDy S20-p
caveolin-2 (rat) FMADDAysHHSVVDy S20-p
S23-p
DDsysHHsGLEyADP
Upstream
Downstream
4 109
Effects on Modified Protein
  • activity, induced
Kinase, in vitro:
  • CK2A1 (human)
Putative in vivo kinases:
  • CK2A1 (human)
Regulatory protein:
  • caveolin-1 (human)
Treatment
  • DRB
  • H-89
  • imatinib
  • LY294002
  • nocodazole
  • staurosporine
  • wortmannin
caveolin-2 (human) DDsysHHsGLEyADP S23-p
caveolin-2 iso2 (human) DDSYSHHSGLEYADP S10
caveolin-2 iso3 (human) DDSYSHHSGLEYADP S23
caveolin-2 (mouse) DDAysHHsGVDyADP S23-p
caveolin-2 (rat) DDAysHHSVVDyTDP S23
Y27-p
sHHsGLEyADPEKFA
Upstream
Downstream
6 41
Effects on Modified Protein
  • intracellular localization
  • phosphorylation
Effects on Biological Processes:
  • cell growth, induced
  • transcription, inhibited
Treatment
  • EGF
  • imatinib
  • nocodazole
  • PP2
  • TGF-beta
  • vanadate
caveolin-2 (human) sHHsGLEyADPEKFA Y27-p
caveolin-2 iso2 (human) SHHSGLEYADPEKFA Y14
caveolin-2 iso3 (human) SHHSGLEYADPEKFA Y27
caveolin-2 (mouse) sHHsGVDyADPEKyV Y27-p
caveolin-2 (rat) sHHSVVDyTDPEKYV Y27-p
F33
EyADPEKFADsDQDR
0 2
caveolin-2 (human) EyADPEKFADsDQDR F33
caveolin-2 iso2 (human) EYADPEKFADSDQDR F20
caveolin-2 iso3 (human) EYADPEKFADSDQDR F33
caveolin-2 (mouse) DyADPEKyVDSSHDR Y33-p
caveolin-2 (rat) DyTDPEKYVDSSQDR Y33
S36-p
DPEKFADsDQDRDPH
Upstream
Downstream
3 11
Effects on Modified Protein
  • activity, induced
Kinase, in vitro:
  • CK2A1 (human)
Putative in vivo kinases:
  • CK2A1 (human)
Regulatory protein:
  • caveolin-1 (human)
Treatment
  • DRB
  • H-89
  • LY294002
  • nocodazole
  • staurosporine
  • wortmannin
caveolin-2 (human) DPEKFADsDQDRDPH S36-p
caveolin-2 iso2 (human) DPEKFADSDQDRDPH S23
caveolin-2 iso3 (human) DPEKFADSDQDRDPH S36
caveolin-2 (mouse) DPEKyVDSSHDRDPH S36
caveolin-2 (rat) DPEKYVDSSQDRDPH S36
S47
RDPHRLNSHLkLGFE
0 1
caveolin-2 (human) RDPHRLNSHLkLGFE S47
caveolin-2 iso2 (human) RDPHRLNSHLKLGFE S34
caveolin-2 iso3 (human) RDPHRLNSHLKDFNA S47
caveolin-2 (mouse) RDPHQLNsHLKLGFE S47-p
caveolin-2 (rat) RDPHQLNSHLKLGFE S47
K50-ub
HRLNSHLkLGFEDVI
0 1
caveolin-2 (human) HRLNSHLkLGFEDVI K50-ub
caveolin-2 iso2 (human) HRLNSHLKLGFEDVI K37
caveolin-2 iso3 (human) under review -
caveolin-2 (mouse) HQLNsHLKLGFEDLI K50
caveolin-2 (rat) HQLNSHLKLGFEDLI K50
T121-p
ILMPFVKtCLMVLPs
0 1
caveolin-2 (human) ILMPFVKtCLMVLPs T121-p
caveolin-2 iso2 (human) ILMPFVKTCLMVLPS T108
caveolin-2 iso3 (human) gap -
caveolin-2 (mouse) ILMPFVKTCLMVLPS T121
caveolin-2 (rat) ILMPFVKTCLMVLPS T121
S128-p
tCLMVLPsVQtIWKs
0 1
caveolin-2 (human) tCLMVLPsVQtIWKs S128-p
caveolin-2 iso2 (human) TCLMVLPSVQTIWKS S115
caveolin-2 iso3 (human) gap -
caveolin-2 (mouse) TCLMVLPSVQTIWKS S128
caveolin-2 (rat) TCLMVLPSVQTIWKS S128
T131-p
MVLPsVQtIWKsVTD
0 1
caveolin-2 (human) MVLPsVQtIWKsVTD T131-p
caveolin-2 iso2 (human) MVLPSVQTIWKSVTD T118
caveolin-2 iso3 (human) gap -
caveolin-2 (mouse) MVLPSVQTIWKSVTD T131
caveolin-2 (rat) MVLPSVQTIWKSVTD T131
S135-p
sVQtIWKsVTDVIIA
Downstream
1 0
Effects on Modified Protein
  • activity, induced
caveolin-2 (human) sVQtIWKsVTDVIIA S135-p
caveolin-2 iso2 (human) SVQTIWKSVTDVIIA S122
caveolin-2 iso3 (human) gap -
caveolin-2 (mouse) SVQTIWKSVTDVVIG S135
caveolin-2 (rat) SVQTIWKSVTDVVIG S135
S153
TSVGRCFSSVSLQLS
0 4
caveolin-2 (human) TSVGRCFSSVSLQLS S153
caveolin-2 iso2 (human) TSVGRCFSSVSLQLS S140
caveolin-2 iso3 (human) gap -
caveolin-2 (mouse) TSVGRSFssVsMQLs S153-p
caveolin-2 (rat) TSVGRIFSSVSMQLS S153
S154
SVGRCFSSVSLQLSQ
0 2
caveolin-2 (human) SVGRCFSSVSLQLSQ S154
caveolin-2 iso2 (human) SVGRCFSSVSLQLSQ S141
caveolin-2 iso3 (human) gap -
caveolin-2 (mouse) SVGRSFssVsMQLsH S154-p
caveolin-2 (rat) SVGRIFSSVSMQLSH S154
S156
GRCFSSVSLQLSQD_
0 3
caveolin-2 (human) GRCFSSVSLQLSQD_ S156
caveolin-2 iso2 (human) GRCFSSVSLQLSQD_ S143
caveolin-2 iso3 (human) gap -
caveolin-2 (mouse) GRSFssVsMQLsHD_ S156-p
caveolin-2 (rat) GRIFSSVSMQLSHD_ S156
S160
SSVSLQLSQD_____
0 1
caveolin-2 (human) SSVSLQLSQD_____ S160
caveolin-2 iso2 (human) SSVSLQLSQD_____ S147
caveolin-2 iso3 (human) gap -
caveolin-2 (mouse) ssVsMQLsHD_____ S160-p
caveolin-2 (rat) SSVSMQLSHD_____ S160